Imagine having the precision of a high-end medical lab shrunk down into a simple test you can use right at the patient's bedside. It works like a molecular search engine that finds specific genetic markers in under 30 minutes. This means doctors don't have to wait days for lab results to decide on critical treatments.
Medical providers must choose between fast but inaccurate tests (immunoassays) or accurate but slow and expensive lab tests (PCR). This delay is critical in life-threatening situations like sepsis or organ transplantation.
The scopeDx platform, a modular diagnostic tool combining CRISPR-Cas specificity with RT-LAMP speed for rapid genetic testing.
If you are a hospital network dealing with slow PCR turnaround times for sepsis or organ transplants — this project developed the scopeDx platform that delivers accurate genetic analysis in under 30 minutes. This removes the bottleneck of centralized labs for time-sensitive decisions.
If you are an IVD manufacturer dealing with the trade-off between speed and accuracy in rapid tests — this project developed a CRISPR-Cas and RT-LAMP hybrid technology that provides SNP-level accuracy. It allows for the creation of portable, high-precision diagnostic kits.
If you are a quality control firm dealing with slow pathogen detection in food chains — this project developed a modular platform that can be adapted for agri-food diagnostics. This enables rapid on-site detection of pathogenic microbes.
The project aims to develop a cost-effective platform that reduces reliance on expensive centralized laboratories and specialized equipment.
Yes, one of the main objectives is to enhance the manufacturing process and develop a standardized platform for multiple applications.
The scopeDx technology is developed and patented by Scope Biosciences, a spin-off from Wageningen University.
The project includes a go-to-market strategy specifically to map out the required regulatory approvals for healthcare use.
The platform enables accurate genetic analysis in under 30 minutes.
The project is led by a single SME, Scope Biosciences B.V., with 100% industry participation. This lean structure suggests a high degree of agility and a direct focus on commercialization, as there are no university or research partners listed in the current consortium phase.
Contact Scope Biosciences B.V. regarding the scopeDx platform
Contact us to explore licensing opportunities for CRISPR-based PoC diagnostics.
